Yang Cheng, Wu Yong-Jian, Qian Jie, Li Jian-Jun
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.
Rev Cardiovasc Med. 2023 Dec 29;24(12):373. doi: 10.31083/j.rcm2412373. eCollection 2023 Dec.
Atherosclerosis, the key pathogenesis of cardiovascular disease, is a leading cause of death and disability worldwide. Statins are first-line lipid-lowering drugs, which have been demonstrated to be powerful agents for anti-atherosclerosis. Numerous studies have confirmed the cardiovascular benefits and long-term safety of statins in a wide range of patients. Statins play an indispensable and irreplaceable part in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). In this article, we summarize the evolution of statins and their role in the treatment of cholesterol. The anti-atherosclerotic mechanism of statins, its efficacy, safety and clinical outcomes in secondary and primary prevention of ACSVD in different patient populations, the combination treatment effects, and guideline recommendations are also detailed. This paper highlights the profound significance of statins as the most successful anti-atherogenic drug in the cardiovascular field.
动脉粥样硬化是心血管疾病的关键发病机制,是全球范围内死亡和残疾的主要原因。他汀类药物是一线降脂药物,已被证明是抗动脉粥样硬化的有力药物。大量研究证实了他汀类药物在广泛患者中的心血管益处和长期安全性。他汀类药物在动脉粥样硬化性心血管疾病(ASCVD)的预防和治疗中发挥着不可或缺且不可替代的作用。在本文中,我们总结了他汀类药物的发展历程及其在胆固醇治疗中的作用。还详细阐述了他汀类药物的抗动脉粥样硬化机制、其在不同患者群体中对ACSVD二级和一级预防的疗效、安全性及临床结局、联合治疗效果以及指南推荐。本文强调了他汀类药物作为心血管领域最成功的抗动脉粥样硬化药物的深远意义。